USA experts recommend Pfizer vaccination for children between the ages of 5 and 11
USA government panel has recommended that children between the ages of 5 and 11 be vaccinated with the Pfizer / Biointech vaccine.
Experts from the US Food and Drug Administration (FDA) have backed a move to vaccinate children between the ages of five and 11, with the BBC saying the way could be opened for emergency vaccinations within a few weeks.
In September, the vaccine company said in a test that the Pfizer / Biointech vaccine was safe for children in that age group. Tests submitted to regulators showed that strong antibodies were produced in children in this age group.
The vaccine has already been given to children over the age of 12 in the United States. The latest decision will benefit 28 million American children.
The decision will take effect after approval from the FDA and CDC (Centers for Disease Control and Prevention). FDA experts also say that the benefits outweigh the health risks of vaccination.
One-third of the vaccine given to adults will be given to children in the age group of 5 to 11 years with the approval. So far, 740,000 people have died from the corona virus in the United States.
Mordana, meanwhile, said on Monday that the test showed that vaccines in the body of children between the ages of 6 and 11 would produce “powerful antibodies to fight the virus” and that the test results would be presented to regulators.
The UK has just started vaccinating children between the ages of 12 and 15. Health officials have recommended a single dose of vaccine for children in that age group.
According to the BBC, the decision to vaccinate children in the age group of 5 to 11 years is historic and has affected other countries as well.
Useful Links: BishalRajwarNepali, BishalRajwarEnglish, AddUnit, OfficerBishal, PolicingStudent, GegreSoft, LBR, KKR, College Of Policing, SocialWorkNepal, WindowsActivate, Jyamuno, PolicingStudent, InnerPeace, Jyamuno, BishalRajwar.com.np, BishalRajwar.com, AddUnit, Nepalese Society, YouTube.
